Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac, as the biotech preps its second Covid-19 shot
The German biotech CureVac released its second quarter update Monday morning, and disclosed among the Covid-19 vaccine highlights that a $600 million-plus oncology partnership with Boehringer Ingelheim has been terminated.
CureVac and Boehringer had been working to develop the mRNA cancer vaccine candidate since 2014, when CureVac received about $45 million upfront and nearly $556 million in promised milestones. Boehringer decided to pull the plug in June, and the termination will become effective this November, the companies said, and a Phase I/II combo therapy study remains ongoing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.